"Pyrrolidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH.
| Descriptor ID |
D011759
|
| MeSH Number(s) |
D03.383.773
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrrolidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrrolidines".
This graph shows the total number of publications written about "Pyrrolidines" by people in this website by year, and whether "Pyrrolidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 3 | 0 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 4 | 5 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 3 | 1 | 4 |
| 2021 | 1 | 2 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 4 | 4 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrrolidines" by people in Profiles.
-
Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Res Commun. 2023 12 19; 3(12):2572-2584.
-
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol. 2023 12; 34(12):1131-1140.
-
Synaptic Loss in Spinocerebellar Ataxia Type 3 Revealed by SV2A Positron Emission Tomography. Mov Disord. 2023 06; 38(6):978-989.
-
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023 04 25; 81(16):1553-1564.
-
Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature. 2022 10; 610(7932):582-591.
-
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study. Hepatology. 2021 07; 74(1):19-27.
-
Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis. Can J Ophthalmol. 2022 02; 57(1):e6-e10.
-
A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation. Brief Bioinform. 2021 03 22; 22(2):1476-1498.